TITLE

Surgical choroidal neovascular membrane removal in the era of anti-vascular endothelial growth factor agents

PUB. DATE
March 2009
SOURCE
Indian Journal of Ophthalmology;Mar2009, Vol. 57 Issue 2, p146
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
36659210

 

Related Articles

  • Anti-VEGF therapy effective in choroidal neovascularization with choroidal osteoma.  // Ocular Surgery News;4/25/2013, Vol. 31 Issue 8, p16 

    The article discusses a research that suggests that choroidal neovascularization and retinal exudation in patients with choroidal osteoma can be regulated with anti-vascular endothelial growth factor (VEGF) therapy.

  • Injections for Wet AMD. Pewitt, Dawn // Review of Optometry;5/15/2004, Vol. 14 Issue 5, p104 

    Investigates how intravitreal injection may help treat choroidal neovascular membranes (CNVM) and possibly improve vision in wet age-related macular degeneration. Diagnosis of CNVM; Types of CNVM; Photodynamic therapy; Anti-vascular endothelial growth factor.

  • Choroidal neovascularization after intraocular foreign body. Fernández-López, Ester; Desco-Esteban, Mari Carmen; Fandiño-López, Adriana; Hernández-Díaz, Mikhail; Navea, Amparo // Clinical Ophthalmology;2014, Vol. 8, p945 

    We report an unusual case of choroidal neovascularization secondary to intraocular foreign body (IOFB) penetrating trauma. A 44-year-old man was referred to our department for IOFB trauma in the right eye. Vitrectomy and IOFB extraction was performed with good visual results. However, 2 months...

  • Anti-VEGF therapy effective in treatment of myopic CNV. Cimberle, Michela // Ocular Surgery News Europe;Jun2012, Vol. 23 Issue 6, p20 

    The article discusses a research study which showed the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in the treatment of patients with myopic choroidal neovascularization (CNV).

  • THE ABCS OF ANTI-VEGF. Ferrucci, Steven // Review of Optometry;11/15/2007 Supplement, Vol. 144, p12 

    The article focuses on the study on anti-vascular endothelial growth factor (anti-VEGF) as treatment option for other retinal diseases. Accordingly, VEGF plays a role in abnormal formation of blood vessels and vascular permeability. Macugen, lucentic and avastin are the anti-VEGF agents...

  • Inhibition of choroidal fibrovascular membrane formation by new class of RNA interference therapeutic agent targeting periostin. Nakama, T; Yoshida, S; Ishikawa, K; Kobayashi, Y; Zhou, Y; Nakao, S; Sassa, Y; Oshima, Y; Takao, K; Shimahara, A; Yoshikawa, K; Hamasaki, T; Ohgi, T; Hayashi, H; Matsuda, A; Kudo, A; Nozaki, M; Ogura, Y; Kuroda, M; Ishibashi, T // Gene Therapy;Feb2015, Vol. 22 Issue 2, p127 

    Age-related macular degeneration (AMD) is a vision-threatening disease characterized by choroidal fibrovascular membrane (FVM) formation, choroidal neovascularization (CNV) and choroidal fibrosis. No safe and effective therapeutic method has been developed for the choroidal fibrosis, although...

  • The Past, Present, and Future of Exudative Age-Related Macular Degeneration Treatment. Barak, Yoreh; Heroman, Wesley J.; Tezel, Tongalp H. // Middle East African Journal of Ophthalmology;Jan-Mar2012, Vol. 19 Issue 1, p43 

    Treatment of exudative age-related macular degeneration has been revolutionized within the last 6 years with the introduction of vascular endothelial growth factor neutralizing agents. Previously popular "destructive treatments," such as laser photocoagulation and photodynamic treatment have...

  • CNV lesions show regression. Charters, Lynda; Cousins, Scott // Ophthalmology Times;11/15/2009, Vol. 34 Issue 22, p29 

    The article features the study made by Dr. Scott Cousins on the efficacy of E10030 anti-platelet-derived growth factor (PDGF) from Ophthotech Corp. and Lucentis anti-vascular endothelial growth factor (VEGF) agent from Genentech Inc. in Fort Lauderdale, Florida. With the combination of PDGF and...

  • Anti-VEGF Therapy to Treat Corneal Neovascularization. Papathanassiou, M.; Theodoropoulou, S.; Analitis, S.; Tzonou, A. // Review of Ophthalmology;Jun2013, Vol. 20 Issue 6, p77 

    The article discusses the role of anti-vascular endothelial growth factor (VEGF) therapy in treatment of corneal neovascularization.

  • ANTI-VEGF THERAPY: SETTING A NEW STANDARD FOR AMD TREATMENT. D'Amico, Donald J.; Packo, Kirk H. // Ophthalmology Times;8/1/2005 Supplement, Vol. 30, p3 

    Highlights developments in the treatment of wet age-related macular degeneration with anti-vascular endothelial growth factor (VEGF) therapy. Ability of VEGF to increase vascular permeability; Approval of pegaptanib for the treatment of all angiographic subtypes; Role of (VEGF) in choroidal...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics